Dx Focus: Clinical and Regulatory PCR and Nucleic Acid Testing News | GenomeWeb

BD Diagnostics has received 510(k) clearance from the US Food and Drug Administration to market its BD Max GBS Assay for Group B Streptococcus on the PCR-based BD Max System.

The current standard of care for prevention of prenatal GBS disease is by screening pregnant women at 35 to 37 weeks by using cultures. Such methods, however, have limited sensitivity, long turnaround time, and depend on highly trained staff to interpret the results, BD said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.